US 2018/0021432 A1 · COMBINATIONS OF INECALCITOL WITH AN ANTI-CD38 AGENT AND THEIR USES FOR TREATING CANCER

Abstract

The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.

Claims17

Dependent claims

A combination of inecalcitol with an anti-CD38 agent.

Dependencies are inferred from the claim text.

Facts

Application

15/655,394Filed 20 Jul 2017

Priority

20 Jul 2016

Published

25 Jan 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/39558
Against materials from animals: against tumor tissues, cells, antigens
A61K 31/047
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates: having two or more hydroxy groups, e.g. sorbitol
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Abstract

Claims17

Dependent claims

A combination of inecalcitol with an anti-CD38 agent.

Dependencies are inferred from the claim text.

Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer

Life of this patent

Abstract

Claims17

Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer

Life of this patent

Abstract

Claims17